<DOC>
	<DOCNO>NCT01452711</DOCNO>
	<brief_summary>The purpose study investigate efficacy TAK-438 , daily ( QD ) , compare lansoprazole patient gastric ulcer .</brief_summary>
	<brief_title>Efficacy TAK-438 Compared AG-1749 ( Lansoprazole ) Treatment Gastric Ulcer</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>1 . Participants must endoscopically confirm gastric ulcer ( mucosal defect white coating ) At least one ulcer white coat 5 mm large size observe baseline ( Visit 1 ) 2 . Outpatient ( include short inpatient examination others ) 1 . Participants gastric ulcer suspect malignant endoscopy baseline ( Visit 1 ) 2 . Participants Acute Gastric Mucosal Lesion ( AGML ) endoscopy baseline ( Visit 1 ) 3 . Participants linear ulcer ( include scar ) endoscopy baseline ( Visit 1 ) 4 . Participants postoperative ulcer ( e.g. , Ulcer EMR/ESD ) endoscopy baseline ( Visit 1 ) 5 . Participants duodenal ulcer endoscopy baseline ( Visit 1 ) 6 . Participants ulcer medical treatment indicate ( e.g. , perforation , pyloric stenosis , duodenal stenosis , large hemorrhage ) 7 . Participants receive endoscopic hemostasis gastric ulcer within 30 day prior baseline ( Visit 1 ) 8 . Participants previous current history ZollingerEllison syndrome , gastric acid hypersecretion disorder 9 . Participants receive scheduled undergo surgery affect gastric acid secretion ( e.g. , resection upper gastrointestinal tract , vagotomy )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>